351 related articles for article (PubMed ID: 15265242)
1. Safety of botulinum toxin type A: a systematic review and meta-analysis.
Naumann M; Jankovic J
Curr Med Res Opin; 2004 Jul; 20(7):981-90. PubMed ID: 15265242
[TBL] [Abstract][Full Text] [Related]
2. Adverse Events of Botulinum Toxin Type A in Facial Rejuvenation: A Systematic Review and Meta-Analysis.
Jia Z; Lu H; Yang X; Jin X; Wu R; Zhao J; Chen L; Qi Z
Aesthetic Plast Surg; 2016 Oct; 40(5):769-77. PubMed ID: 27495260
[TBL] [Abstract][Full Text] [Related]
3. A preliminary comparison of the efficacy and tolerability of botulinum toxin serotypes A and B in the treatment of myofascial pain syndrome: a retrospective, open-label chart review.
Lang AM
Clin Ther; 2003 Aug; 25(8):2268-78. PubMed ID: 14512133
[TBL] [Abstract][Full Text] [Related]
4. Botulinum toxin type A (BOTOX) for treatment of migraine.
Binder WJ; Brin MF; Blitzer A; Pogoda JM
Dis Mon; 2002 May; 48(5):323-35. PubMed ID: 12195263
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Botulinum Toxin Type A in the Treatment of Glabellar Lines: A Meta-Analysis of Randomized, Placebo-Controlled, Double-Blind Trials.
Guo Y; Lu Y; Liu T; Zhou Y; Yang P; Zhu J; Chen L; Yang Q
Plast Reconstr Surg; 2015 Sep; 136(3):310e-318e. PubMed ID: 26313835
[TBL] [Abstract][Full Text] [Related]
6. Botulinum toxin for glabellar lines: a review of the efficacy and safety of currently available products.
Dessy LA; Fallico N; Mazzocchi M; Scuderi N
Am J Clin Dermatol; 2011 Dec; 12(6):377-88. PubMed ID: 21877763
[TBL] [Abstract][Full Text] [Related]
7. A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia.
Naumann M; Yakovleff A; Durif F;
J Neurol; 2002 Jan; 249(1):57-63. PubMed ID: 11954869
[TBL] [Abstract][Full Text] [Related]
8. A pilot study of botulinum toxin A for male chronic pelvic pain syndrome.
Gottsch HP; Yang CC; Berger RE
Scand J Urol Nephrol; 2011 Feb; 45(1):72-6. PubMed ID: 21062115
[TBL] [Abstract][Full Text] [Related]
9. Botulinum toxin for the management of bladder dysfunction.
Schurch B
Drugs; 2006; 66(10):1301-18. PubMed ID: 16903766
[TBL] [Abstract][Full Text] [Related]
10. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines.
Carruthers JA; Lowe NJ; Menter MA; Gibson J; Nordquist M; Mordaunt J; Walker P; Eadie N;
J Am Acad Dermatol; 2002 Jun; 46(6):840-9. PubMed ID: 12063480
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of botulinum toxin injection for benign prostatic hyperplasia: a systematic review and meta-analysis.
Shim SR; Cho YJ; Shin IS; Kim JH
Int Urol Nephrol; 2016 Jan; 48(1):19-30. PubMed ID: 26560471
[TBL] [Abstract][Full Text] [Related]
12. Sixth nerve palsy following botulinum toxin injection for facial rejuvenation.
Dolar Bilge A; Sadigov F; Salar-Gomceli S
Cutan Ocul Toxicol; 2017 Jun; 36(2):193-194. PubMed ID: 27558865
[TBL] [Abstract][Full Text] [Related]
13. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke.
Brashear A; Gordon MF; Elovic E; Kassicieh VD; Marciniak C; Do M; Lee CH; Jenkins S; Turkel C;
N Engl J Med; 2002 Aug; 347(6):395-400. PubMed ID: 12167681
[TBL] [Abstract][Full Text] [Related]
14. [Botulinum toxin for the treatment of major depressive disorder].
Hawlik AE; Freudenmann RW; Pinkhardt EH; Schönfeldt-Lecuona CJ; Gahr M
Fortschr Neurol Psychiatr; 2014 Feb; 82(2):93-9. PubMed ID: 24519192
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of botulinum toxin type A in treatment of trigeminal neuralgia and peripheral neuropathic pain: A meta-analysis of randomized controlled trials.
Wei J; Zhu X; Yang G; Shen J; Xie P; Zuo X; Xia L; Han Q; Zhao Y
Brain Behav; 2019 Oct; 9(10):e01409. PubMed ID: 31541518
[TBL] [Abstract][Full Text] [Related]
16. Botulinum toxin type A and neurogenic urinary incontinence: sometimes beneficial, if used safely.
Prescrire Int; 2013 Jan; 22(134):12-3. PubMed ID: 23367677
[TBL] [Abstract][Full Text] [Related]
17. Pooled analysis of the safety of botulinum toxin type A in the treatment of poststroke spasticity.
Turkel CC; Bowen B; Liu J; Brin MF
Arch Phys Med Rehabil; 2006 Jun; 87(6):786-92. PubMed ID: 16731213
[TBL] [Abstract][Full Text] [Related]
18. Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group.
Silberstein S; Mathew N; Saper J; Jenkins S
Headache; 2000 Jun; 40(6):445-50. PubMed ID: 10849039
[TBL] [Abstract][Full Text] [Related]
19. Early Botulinum Toxin Injections in Infants With Musculoskeletal Disorders: A Systematic Review of Safety and Effectiveness.
Bourseul JS; Molina A; Lintanf M; Houx L; Chaléat-Valayer E; Pons C; Brochard S
Arch Phys Med Rehabil; 2018 Jun; 99(6):1160-1176.e5. PubMed ID: 29288113
[TBL] [Abstract][Full Text] [Related]
20. Botulinum toxin therapy for temporomandibular joint disorders: a systematic review of randomized controlled trials.
Chen YW; Chiu YW; Chen CY; Chuang SK
Int J Oral Maxillofac Surg; 2015 Aug; 44(8):1018-26. PubMed ID: 25920597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
